EUVIMEDEUVIMED entdecken
Crossref

Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors

Yue Cheng iD, Tianran Li iD, Mengru Wang iD, Chuan Lan iD, Haizhen Fan, Zhicheng He, Qing Liu, Fei Li, Lujing Wang, Wenying Wang, Gehao Chen, Tunan Chen iD und 23 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aed1155 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Yue Cheng und 34 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pathology & Southwest Cancer Center, First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical U…. Hauptthemen laut MEDLINE: Phagocytosis, Wiskott-Aldrich Syndrome Protein, Macrophages, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Chongqing, Science and Technology Innovation Key R&D.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Both primary and metastatic brain malignancies are fatal and highly infiltrated with tumor-associated macrophages (TAMs). Enhancing the phagocytosis of neoplastic cells by TAMs is pivotal for slowing tumor growth. Great endeavors have been made to develop tyrosine kinase inhibitors (TKIs) for brain malignancies, yet whether tumor-targeting TKIs affect the phagocytic capacity of TAMs remains largely unknown. In this preclinical study, we report that repurposing ibrutinib, a blood-brain barrier–penetrable TKI, effectively suppresses the growth of several primary and metastatic brain tumors highly expressing Bruton’s tyrosine kinase (BTK) or bone marrow X-linked nonreceptor tyrosine kinase (BMX) but concurrently dampens the TAM phagocytic function. Mechanistically, BTK, which is activated in TAMs, interacts with and phosphorylates Wiskott-Aldrich syndrome protein (WASp) to organize the actin cytoskeleton, which is imperative for phagocytosis. Ibrutinib treatment disrupts BTK-mediated WASp activation, thereby compromising TAM phagocytic efficacy. Pharmacological activation of WASp by its selective small-molecular activator EG-011 restores the ibrutinib-impaired TAM engulfment of tumor cells and effectively improves ibrutinib efficacy in mice bearing glioblastomas, primary central nervous system lymphomas, and lung carcinoma brain metastases. Furthermore, elevated expression of phosphorylated BTK or phosphorylated WASp in TAMs correlates with an increased phagocytic TAM subset identified by single-cell RNA sequencing and correlates with prolonged patient survival in a cohort with glioblastoma. Our preclinical study highlights the necessity of evaluating the on-target, off-tumor attack of TAMs during TKI administration and provides a proof of concept for reinvigorating the TAM phagocytic function to achieve additional clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PhagocytosisWiskott-Aldrich Syndrome ProteinMacrophagesBrain NeoplasmsPyrimidinesPyrazolesAnimalsPiperidinesAdenineHumansAgammaglobulinaemia Tyrosine KinaseDisease Models, AnimalCell Line, TumorMicePhosphorylationProtein Kinase InhibitorsProtein-Tyrosine Kinases

Substanzen

ibrutinibPiperidinesAdenineWiskott-Aldrich Syndrome ProteinPyrimidinesAgammaglobulinaemia Tyrosine KinasePyrazolesProtein Kinase InhibitorsProtein-Tyrosine Kinases

Autor:innen und Institutionen

  • Institute of Pathology & Southwest Cancer Center, First Affiliated Hospital (Southwest Hospital) and School of Basic Medical Sciences, Army Medical University (Third Military Medical University), and the Key Laboratory…
  • Shigatse Branch, Xinqiao Hospital, Army Medical University, Chongqing 857000, Tibet Autonomous Region, China.
  • Department of Neurosurgery and Glioma Medical Research Center, Southwest Hospital, Army Medical University, Chongqing 400038, China.
  • School of Medicine, Chongqing University, Chongqing 400030, China.
  • Department of Blood Transfusion, Southwest Hospital, Army Medical University, Chongqing 400038, China.
  • Chongqing Yuyue Scientific Research Center for Pathology, Chongqing Institute of Advanced Pathology, Jinfeng Laboratory, Chongqing 400039, China.

ORCID-Profile: Yue Cheng, Tianran Li, Mengru Wang, Chuan Lan, Tunan Chen, Chao Wang, Xia Zhang, Rong Hu, Yi-Fang Ping, Xiu-Wu Bian, Yu Shi

Förderung

  • National Natural Science Foundation of China
  • Natural Science Foundation of Chongqing
  • Science and Technology Innovation Key R&D
  • Municipal Health Commission of Chongqing
  • Chongqing Scientific and Technological Commission

Zitieren

APA

Cheng, Y., Li, T., Wang, M., Lan, C., Fan, H., He, Z., Liu, Q., Li, F., Wang, L., Wang, W., Chen, G., Chen, T., Mao, M., Ruan, Q., Wang, L., Zhang, X., Qi, H., Zhang, Y., Zhou, X., …, & Shi, Y. (2026). Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aed1155

Vancouver

Cheng Y, Li T, Wang M, Lan C, Fan H, He Z, et al. Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aed1155

BibTeX
@article{Cheng2026,
  author = {Cheng, Yue and Li, Tianran and Wang, Mengru and Lan, Chuan and Fan, Haizhen and He, Zhicheng and Liu, Qing and Li, Fei and Wang, Lujing and Wang, Wenying and Chen, Gehao and Chen, Tunan and Mao, Min and Ruan, Qianying and Wang, Lixia and Zhang, Xiaoning and Qi, Haoyue and Zhang, Yi and Zhou, Xinyue and Duan, Jiayu and Luo, Chunhua and Wang, Chao and Ye, Shuanghui and Kong, Weikai and Guo, Haitao and Niu, Qin and Qin, Zhen and Yan, Qing and Ma, Qinghua and Zhang, Xia and Hu, Rong and Feng, Hua and Ping, Yi-Fang and Bian, Xiu-Wu and Shi, Yu},
  title = {Pharmacological activation of WASp potentiates macrophage phagocytosis and enhances ibrutinib efficacy against mouse models of brain tumors},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aed1155}
}
Kostenlos starten →